These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 23719879)

  • 1. Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia.
    Radvansky LJ; Pace MB; Siddiqui A
    Am J Health Syst Pharm; 2013 Jun; 70(12):1025-32. PubMed ID: 23719879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of head and neck cancers: issues for clinical pharmacists.
    Scarpace SL; Brodzik FA; Mehdi S; Belgam R
    Pharmacotherapy; 2009 May; 29(5):578-92. PubMed ID: 19397465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of saliva in oral health: strategies for prevention and management of xerostomia.
    Brosky ME
    J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to reduce radiation-related toxicity in patients with cancer of the head and neck.
    Garden AS; Lewin JS; Chambers MS
    Curr Oncol Rep; 2006 Mar; 8(2):140-5. PubMed ID: 16507224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
    Sasse AD; Clark LG; Sasse EC; Clark OA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological modulation of radiation-induced oral mucosal complications.
    Bockel S; Vallard A; Lévy A; François S; Bourdis M; Le Gallic C; Riccobono D; Annede P; Drouet M; Tao Y; Blanchard P; Deutsch É; Magné N; Chargari C
    Cancer Radiother; 2018 Sep; 22(5):429-437. PubMed ID: 29776830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
    Clémenson C; Liu W; Bricout D; Soyez-Herkert L; Chargari C; Mondini M; Haddad R; Wang-Zhang X; Benel L; Bloy C; Deutsch E
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1141-1152. PubMed ID: 31063799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of salivary hypofunction during and after radiotherapy.
    Shiboski CH; Hodgson TA; Ship JA; Schiødt M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

  • 16. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amifostine in the management of radiation-induced and chemo-induced mucositis.
    Bensadoun RJ; Schubert MM; Lalla RV; Keefe D
    Support Care Cancer; 2006 Jun; 14(6):566-72. PubMed ID: 16586122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches to preventing xerostomia.
    J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.